Therapeutic strategies to treat CNS pathology in mucopolysaccharidoses

Patent metadata

Field	Value
Publication number	US-9206401-B2
Application number	US-201013996386-A
Country	US
Kind code	B2
Filing date	Dec 22, 2010
Priority date	Dec 22, 2010
Publication date	Dec 8, 2015
Grant date	Dec 8, 2015

Abstract

The invention provides for nucleotide sequences encoding for a chimeric sulfatase, viral vectors expressing such sequences for gene therapy and pharmaceutical uses of the chimeric expressed protein. The invention is particularly applied in the therapy of mucopolysaccharidosis, preferably type IIIA.

First claim

The invention claimed is:

1. A method for treating a human subject diagnosed with a mucopolysaccharidoses (MPS) pathology, comprising administering to the subject a suitable amount of a pharmaceutical composition comprising a viral vector, via a systemic route of administration,
wherein the MPS pathology is MPS type IIIA,
wherein the viral vector comprises a recombinant plasmid suitable for gene therapy of MPS type IIIA,
wherein the recombinant plasmid comprises a nucleotide sequence encoding for a chimeric sulfatase, said chimeric sulfatase consisting essentially of, in the N-terminal to C-terminal sequence order of:
a) a signal peptide derived from either the human α-antitrypsin (hAAT) amino acid sequence or the human Iduronate-2-sulfatase (IDS) amino acid sequence;
b) a human sulfatase derived amino acid sequence deprived of its signal peptide;
c) the ApoB LDLR-binding domain; and

wherein the human sulfatase is human sulfamidase.

2. A method for treating a human subject diagnosed with mucopolysaccharidoses (MPS) pathology comprising administering to the subject in need thereof a suitable amount of a pharmaceutical composition comprising a chimeric sulfatase;
wherein the MPS pathology is MPS type IIIA,
wherein the chimeric sulfatase consists essentially, in the N-terminal to C-terminal sequence order, of:
a) a signal peptide derived from either the human α-antitrypsin (hAAT) amino acid sequence or the human Iduronate-2-sulfatase (IDS) amino acid sequence;
b) a human sulfatase derived amino acid sequence deprived of its signal peptide; and
c) the ApoB LDLR-binding domain;
wherein the human sulfatase is human sulfamidase.

3. The method according to claim 1 , wherein the signal peptide has the sequence of SEQ ID NO: 2 or SEQ ID NO: 4.

4. The method according to claim 1 , wherein the encoded human sulfamidase derived amino acid sequence consists essentially of SEQ ID NO: 8.

5. The method according to claim 1 , wherein the encoded ApoB LDLR-binding domain consists essentially of SEQ ID NO: 10.

6. The method according to claim 1 , wherein the nucleotide sequence is selected from the group consisting of:
a) Assembly hAATsp-SGSH-3xflag-ApoB cassette (SEQ ID NO: 15),
b) Assembly hIDSsp-SGSH-3xflag-ApoB cassette (SEQ ID NO: 17),
c) Assembly hAATsp-SGSH-ApoB cassette (SEQ ID NO: 23) and
d) Assembly hIDSsp-SGSH-ApoB cassette (SEQ ID NO: 25).

7. The method according to claim 1 , wherein the nucleotide sequence is under the control of a liver specific promoter.

8. The method according to claim 7 wherein the liver specific promoter is the human thyroid hormone-globulin (TBG) promoter.

9. The method according to claim 1 wherein the viral vector is selected from the group consisting of lentiviral vectors, helper-dependent adenoviral vectors or AAV vectors.

10. The method according to claim 1 wherein the recombinant plasmid is AAV2.1.

11. The method according to claim 1 wherein the viral vector is an AAV viral vector.

12. The method according to claim 11 wherein the viral vector is an AAV serotype 8vector.

13. The method according to claim 2 , wherein the signal peptide has the sequence of SEQ ID NO: 2 or SEQ ID NO: 4.

14. (Withdrawn/New) The method according to claim 2 , wherein the encoded human sulfamidase derived amino acid sequence consists essentially of SEQ ID NO: 8.

15. The method according to claim 2 , wherein the encoded ApoB LDLR-binding domain consists essentially of SEQ ID NO: 10.

16. The method according to claim 2 , wherein the chimeric sulfatase comprises a sequence selected from the group consisting of:
a) hAATsp-SGSH-3xflag-ApoB aminoacid sequence (SEQ ID NO: 16),
b) hIDSsp-SGSH-3xflag-ApoB aminoacid sequence (SEQ ID NO: 18),
c) hAATsp-SGSH-ApoB aminoacid sequence (SEQ ID NO: 24) and
d) hIDSsp-SGSH-ApoB aminoacid sequence (SEQ ID NO: 26).

17. The method according to claim 8 wherein the human thyroid hormone-globulin (TBG) promoter comprises SEQ ID NO: 27.

18. The method according to claim 1 wherein the pharmaceutical composition consists of the viral vector.

19. The method according to claim 2 wherein the pharmaceutical composition consists of the chimeric sulfatase.

Assignees

• Ballabio Andrea
• Fraldi Alessandro
• Fond Telethon

Inventors

• Ballabio Andrea
• Fraldi Alessandro

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• C07K2319/74

  containing a fusion for binding to a cell surface receptor · CPC title

• C07K2319/33

  fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies · CPC title

• C07K2319/02

  containing a signal sequence · CPC title

• C07K14/8125

  Alpha-1-antitrypsin · CPC title